Business
Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results
Conference call and webcast scheduled for Tuesday, August 8, 4:30 p.m. Eastern Time. BRISBANE, Calif.--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (Nasdaq:
About this update from Sangamo Therapeutics, Inc.
[{"type":"text","content":"\nConference call and webcast scheduled for Tuesday, August 8, 4:30 p.m. Eastern Time.\n\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nSangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2023 financial results.\n\n\n“I am extremely proud of our significant progress this quarter. We are pleased to have executed several business development deals, demonstrating the excitement in Sangamo’s science and platform,” said Sandy Macrae, Chief Executive Officer of Sangamo. “We continue to make progress in our clinical programs, with productive written feedback received from the FDA on our Fabry Phase 3 strategy, and initial approvals received on our amended TX200 protocol to accelerate dose escalation. The impressive data we presented this quarter on our preclinical neurology and AAV capsid delivery capabilities reinforces our scientific capabilities, which continue to lay the foundation for the company’s future.”\n\n\nRecent Business Highlights\n\n\nCorporate Updates\n\n\n\nAnnounced research evaluation and option agreement with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, for novel engineered cerebrospinal fluid-administered capsids with enhanced nervous system delivery. We have granted Prevail rights to evaluate our proprietary adeno-associated virus (AAV) capsids developed through our AAV capsid engineering platform, SIFTER, in exchange for an upfront payment. If Prevail exercises the option to license the capsids, then we will become eligible to earn exercise fees and potential development and commercial milestones of up to $1.2 billion and tiered royalties on potential sales of products using the capsids.\n\n\n\nAnnounced research evaluation and option agreement with Chroma Medicine to explore zinc finger proteins (ZFPs) for epigenetic editing. We have granted Chroma rights to evaluate our novel ZFPs in specified targets outside of the central nervous system in exchange for an upfront payment. If Chroma exercises the option to license the ZFPs, then we will become eligible to earn exercise fees, potential development and commercial milestone payments and tiered royalties on potential sales of products using the ZFPs.\n\n\n\nProgram Highlights\n\n\nFabry Disease – Dosed total of 22 patients in Phase 1/2 STAAR study; received Fast ...